Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Tessara’s RealBrain technology replicates the human brain’s complexity, and Neurizon is utilizing these models to explore NUZ ...

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Stockhead’s Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Michael Thurn about the company's goal ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Neurizon Therapeutics' (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with ...

In a big step forward in the development of NUZ-001, Neurizon teams up with Tessara for further testing on its lead candidate.

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.